drugset / Trial / NCT03609294

A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers

NCT03609294

Phase 1 Completed 67 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety/tolerability when administrated fixed dose combination of Fimasartan/Linagliptin and when co-administrated Fimasartan and Linagliptin.

Timeline

Start
2018-07-18
Primary completion
2019-03-04
Completion
2019-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Fimasartan Small molecule 120 mg
Subject Linagliptin Small molecule 5 mg